CRISPR 유전체 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 질환 유형별, 치료 유형별, 투여 방법별, 최종사용자별, 표적 유전자 변형별, 지역별, 경쟁별(2020-2030년)

Crispr Genomic Cure Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Therapy Type, By Delivery Method, By End User, By Targeted Genetic Modification, By Region & Competition, 2020-2030F

US $ 4,500 ￦ 6,385,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,805,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,352,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

CRISPR 유전체 치료 세계 시장 규모는 2024년 29억 5,000만 달러로 평가되며, 2030년까지 CAGR 25.15%로 예측 기간 동안 괄목할 만한 성장이 예상됩니다.

세계의 CRISPR 유전체 치료 시장은 생명공학 및 의료 산업에서 빠르게 발전하고 있는 분야입니다. CRISPR(Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR) 기술은 유전자 편집에 혁명을 가져왔으며, 다양한 유전질환을 치료할 수 있는 잠재력을 가지고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	29억 5,000만 달러
시장 규모 : 2030년	113억 6,000만 달러
CAGR : 2025-2030년	25.15%
급성장 부문	유전성 질환
최대 시장	북미

시장 촉진요인

유전성 질환 및 만성질환의 유병률 증가

주요 시장 과제

윤리적, 규제적 장애물

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 CRISPR 유전체 치료 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 질환 유형별(유전성 질환, 암, 감염증, 신경질환, 심혈관질환, 혈액질환, 대사질환, 기타)
  • 치료 유형별(유전자 편집, 유전자 치료, 세포 치료, 면역요법)
  • 투여 방법별(생체내, 생체외)
  • 최종사용자별(병원 클리닉, 연구기관, 바이오테크놀러지·제약회사)
  • 표적 유전자 변형별(단일 유전자 변형, 복수 유전자 변형, 유전체 전체 변형)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 CRISPR 유전체 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 캐나다
  • 멕시코

제7장 유럽의 CRISPR 유전체 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 CRISPR 유전체 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 CRISPR 유전체 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 CRISPR 유전체 치료 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 제품 출시
• 인수합병

제13장 세계의 CRISPR 유전체 치료 시장 : SWOT 분석

제14장 경쟁 구도

• Merck KGaA
• Takara Bio Inc
• Lonza Group AG
• Horizon Discovery Group Ltd
• Genscript BIoTech Corp
• Synthego Corp
• Precision BioSciences Inc
• Mammoth Biosciences Inc
• Thermo Fisher Scientific Inc
• Intellia Therapeutics Inc.

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

ksm

영문 목차

영문목차

Global Crispr Genomic Cure Market was valued at USD 2.95 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 25.15% through 2030. The global CRISPR genomic cure market is a rapidly evolving sector within the biotechnology and healthcare industries. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized gene editing and holds immense promise for treating various genetic and hereditary diseases.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.95 Billion
Market Size 2030	USD 11.36 Billion
CAGR 2025-2030	25.15%
Fastest Growing Segment	Genetic Disorders
Largest Market	North America

Key Market Drivers

Increasing Prevalence of Genetic Disorders and Chronic Diseases

The growing incidence of genetic disorders and chronic diseases is a major driver behind the rapid expansion of the Global CRISPR Genomic Cure Market. Genetic disorders and congenital abnormalities affect approximately 2%-5% of all live births, contributing to up to 30% of pediatric hospital admissions and accounting for nearly 50% of childhood mortality in industrialized nations. These figures highlight a critical demand for advanced genomic interventions, positioning CRISPR-based therapies as a transformative solution in pediatric healthcare. As the burden of hereditary and chronic illnesses continues to rise worldwide, there is an increasing demand for innovative, targeted, and long-term solutions to treat these conditions. CRISPR-based gene editing has emerged as a groundbreaking approach, offering precise and potentially curative treatments for diseases with a strong genetic basis. The incidence of genetic disorders and chronic diseases is increasing due to factors such as aging populations, environmental influences, and inherited genetic mutations. Annually,

Key Market Challenges

Ethical and Regulatory Hurdles

Perhaps one of the most significant challenges is the ethical and regulatory landscape surrounding CRISPR technology. The ethical debate over gene editing in humans, particularly germline editing, remains a contentious issue. Regulatory agencies worldwide are grappling with the need to strike a balance between fostering innovation and ensuring safety and ethical considerations.

Key Market Players

• Merck KGaA
• Takara Bio Inc
• Lonza Group AG
• Horizon Discovery Group Ltd
• Genscript Biotech Corp
• Synthego Corp
• Precision BioSciences Inc
• Mammoth Biosciences Inc
• Thermo Fisher Scientific Inc
• Intellia Therapeutics Inc

Report Scope:

In this report, the Global Crispr Genomic Cure Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Crispr Genomic Cure Market, By Disease Type:

• Genetic Disorders
• Cancer
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Disorders
• Blood Disorders
• Metabolic Disorders
• Others

Crispr Genomic Cure Market, By Therapy Type:

• Gene Editing
• Gene Therapy
• Cell Therapy
• Immunotherapy

Crispr Genomic Cure Market, By Delivery Method:

• In vivo
• Ex vivo

Crispr Genomic Cure Market, By End User:

• Hospitals & Clinics
• Research Institutes
• Biotechnology & Pharmaceutical Companies

Crispr Genomic Cure Market, By Targeted Genetic Modification:

• Single Gene Modification
• Multiple Gene Modification
• Genome-wide Modification

Crispr Genomic Cure Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Crispr Genomic Cure Market.

Available Customizations:

Global Crispr Genomic Cure market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Crispr Genomic Cure Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
  • 5.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
  • 5.2.3. By Delivery Method (In vivo, Ex vivo)
  • 5.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
  • 5.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Crispr Genomic Cure Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Therapy Type
  • 6.2.3. By Delivery Method
  • 6.2.4. By End User
  • 6.2.5. By Targeted Genetic Modification
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Crispr Genomic Cure Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Therapy Type
      • 6.3.1.2.3. By Delivery Method
      • 6.3.1.2.4. By End User
      • 6.3.1.2.5. By Targeted Genetic Modification
  • 6.3.2. Canada Crispr Genomic Cure Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Therapy Type
      • 6.3.2.2.3. By Delivery Method
      • 6.3.2.2.4. By End User
      • 6.3.2.2.5. By Targeted Genetic Modification
  • 6.3.3. Mexico Crispr Genomic Cure Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Therapy Type
      • 6.3.3.2.3. By Delivery Method
      • 6.3.3.2.4. By End User
      • 6.3.3.2.5. By Targeted Genetic Modification

7. Europe Crispr Genomic Cure Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Therapy Type
  • 7.2.3. By Delivery Method
  • 7.2.4. By End User
  • 7.2.5. By Targeted Genetic Modification
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Crispr Genomic Cure Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Therapy Type
      • 7.3.1.2.3. By Delivery Method
      • 7.3.1.2.4. By End User
      • 7.3.1.2.5. By Targeted Genetic Modification
  • 7.3.2. United Kingdom Crispr Genomic Cure Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Therapy Type
      • 7.3.2.2.3. By Delivery Method
      • 7.3.2.2.4. By End User
      • 7.3.2.2.5. By Targeted Genetic Modification
  • 7.3.3. Italy Crispr Genomic Cure Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Therapy Type
      • 7.3.3.2.3. By Delivery Method
      • 7.3.3.2.4. By End User
      • 7.3.3.2.5. By Targeted Genetic Modification
  • 7.3.4. France Crispr Genomic Cure Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Therapy Type
      • 7.3.4.2.3. By Delivery Method
      • 7.3.4.2.4. By End User
      • 7.3.4.2.5. By Targeted Genetic Modification
  • 7.3.5. Spain Crispr Genomic Cure Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Therapy Type
      • 7.3.5.2.3. By Delivery Method
      • 7.3.5.2.4. By End User
      • 7.3.5.2.5. By Targeted Genetic Modification

8. Asia-Pacific Crispr Genomic Cure Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Therapy Type
  • 8.2.3. By Delivery Method
  • 8.2.4. By End User
  • 8.2.5. By Targeted Genetic Modification
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Crispr Genomic Cure Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Therapy Type
      • 8.3.1.2.3. By Delivery Method
      • 8.3.1.2.4. By End User
      • 8.3.1.2.5. By Targeted Genetic Modification
  • 8.3.2. India Crispr Genomic Cure Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Therapy Type
      • 8.3.2.2.3. By Delivery Method
      • 8.3.2.2.4. By End User
      • 8.3.2.2.5. By Targeted Genetic Modification
  • 8.3.3. Japan Crispr Genomic Cure Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Therapy Type
      • 8.3.3.2.3. By Delivery Method
      • 8.3.3.2.4. By End User
      • 8.3.3.2.5. By Targeted Genetic Modification
  • 8.3.4. South Korea Crispr Genomic Cure Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Therapy Type
      • 8.3.4.2.3. By Delivery Method
      • 8.3.4.2.4. By End User
      • 8.3.4.2.5. By Targeted Genetic Modification
  • 8.3.5. Australia Crispr Genomic Cure Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Therapy Type
      • 8.3.5.2.3. By Delivery Method
      • 8.3.5.2.4. By End User
      • 8.3.5.2.5. By Targeted Genetic Modification

9. South America Crispr Genomic Cure Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Therapy Type
  • 9.2.3. By Delivery Method
  • 9.2.4. By End User
  • 9.2.5. By Targeted Genetic Modification
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Crispr Genomic Cure Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Therapy Type
      • 9.3.1.2.3. By Delivery Method
      • 9.3.1.2.4. By End User
      • 9.3.1.2.5. By Targeted Genetic Modification
  • 9.3.2. Argentina Crispr Genomic Cure Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Therapy Type
      • 9.3.2.2.3. By Delivery Method
      • 9.3.2.2.4. By End User
      • 9.3.2.2.5. By Targeted Genetic Modification
  • 9.3.3. Colombia Crispr Genomic Cure Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Therapy Type
      • 9.3.3.2.3. By Delivery Method
      • 9.3.3.2.4. By End User
      • 9.3.3.2.5. By Targeted Genetic Modification

10. Middle East and Africa Crispr Genomic Cure Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Therapy Type
  • 10.2.3. By Delivery Method
  • 10.2.4. By End User
  • 10.2.5. By Targeted Genetic Modification
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Crispr Genomic Cure Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Therapy Type
      • 10.3.1.2.3. By Delivery Method
      • 10.3.1.2.4. By End User
      • 10.3.1.2.5. By Targeted Genetic Modification
  • 10.3.2. Saudi Arabia Crispr Genomic Cure Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Therapy Type
      • 10.3.2.2.3. By Delivery Method
      • 10.3.2.2.4. By End User
      • 10.3.2.2.5. By Targeted Genetic Modification
  • 10.3.3. UAE Crispr Genomic Cure Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Therapy Type
      • 10.3.3.2.3. By Delivery Method
      • 10.3.3.2.4. By End User
      • 10.3.3.2.5. By Targeted Genetic Modification

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Crispr Genomic Cure Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Merck KGaA
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Takara Bio Inc
• 14.3. Lonza Group AG
• 14.4. Horizon Discovery Group Ltd
• 14.5. Genscript Biotech Corp
• 14.6. Synthego Corp
• 14.7. Precision BioSciences Inc
• 14.8. Mammoth Biosciences Inc
• 14.9. Thermo Fisher Scientific Inc
• 14.10.Intellia Therapeutics Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료